M-NIMBS Banner
Dhtml Menu Css by Vista-Buttons.com v5.7
Our Mission

The Michigan Nanotechnology Institute for Medicine and Biological Sciences is a true multidisciplinary team of chemists, physicists, engineers, toxicologists, physicians, biologists, pharmacists, and (bio)informatics specialists collaborating on nanoscience in biology and medicine. The Institute involves approximately 60 faculty in a "no-walls" model using facilities in the Engineering, Medical and LS&A schools to enhance competitiveness for externally funded grants and contracts.

We have three goals:

~  First, to facilitate interaction among diverse scientific disciplines to accelerate discovery in Nanomedicine.

~  Second, to foster translational science with the goal to commercialize our discoveries.

~  Third, to fulfill our educational mission to build a multidisciplinary Rackham Graduate School Certificate program in Nanobiology, and to design a minor in Nanobiology for undergraduate students.

Students: see our nanobiology graduate program and Seminar series

BlueLine

Current News and Events:

March 26, 2014

Merck Licenses NanoBio Technology

Associated Press

ANN ARBOR, Mich., - NanoBio Corporation today announced a licensing agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for the use of its nanoemulsion (NE) adjuvant technology.

Under the agreement, Merck receives exclusive rights to NanoBio's NE adjuvant for use in an intranasal respiratory syncytial virus (RSV) vaccine and non-exclusive rights for use in an intranasal seasonal influenza and/or universal seasonal influenza ("Flu") vaccine. NanoBio receives an upfront payment and is eligible to receive milestone payments based on Merck RSV and Flu vaccine candidates' development and regulatory approvals, as well as royalties on sales of any Merck RSV or Flu vaccines that ultimately use the NanoBio NE adjuvant technology.

NanoBio's NanoStat@ technology platform employs a novel oil-in-water nanoemulsion that can incorporate, deliver and adjuvant multiple antigen types. The NE adjuvant is effective when administered via intranasal, intramuscular or subcutaneous vaccination. In recent studies, NanoBio has demonstrated that intranasal vaccination elicits robust systemic and mucosal immunity, thereby offering enhanced protection against respiratory infections and sexually transmitted diseases compared to intramuscular vaccination.

"We've collaborated with Merck on research in RSV since 2011 and are very pleased to broaden our relationship with this license agreement covering vaccine candidates for two respiratory diseases," said David Peralta, chief executive officer of NanoBio. "Merck's demonstrated leadership in developing and marketing vaccines makes them an ideal partner for NanoBio."

This is an example of successful translational research. The RSV NE adjuvant vaccine technology was originally developed at the Michigan Nanotechnology Institute for Medicine and Biological Sciences in collaboration with NanoBio Corp. with a $1,997,507 grant from the Bill and Melinda Gates Foundation.

 

Introduction to Life Science Technology Commercialization Symposium

Friday June 1, 2012

8:30am to 6:00pm

Location: Research Auditorium, Building 10, North Campus Research Complex, University of Michigan

The translation and commercialization of Life Science Technology is receiving increased attention both nationally and at the University of Michigan.  The Introduction to Life Science Technology Commercialization Symposium will provide an overview of the different paths that can be taken for successful technology commercialization as well as the key factors that should be considered.  Speakers include faculty who have successfully commercialized University Technology and nationally recognized members of the venture capital and business communities.  

University of Michigan Faculty, Graduate Students and Post-docs with an interest in the commercialization of life science technologies (therapeutics, diagnostics, medical devices and life science tools) should attend this event. 

 

This event is a collaboration between the Michigan Nanotechnology Institute for Medicine and Biological Sciences, Rackham Graduate School, the College of Engineering Center for Entrepreneurship, Medical School Business Development, the Medical Innovation Center, the Ross School of Business Zell Lurie Institute for Entrepreneurial Studies and the Unit for Laboratory Animal Medicine. 

Click here for the agenda

This Symposium was very sucessful

 

 

More News

© The Michigan Nanotechnology Institute for Medicine and Biological Sciences (MNIMBS)® 2010
MNIMBS is a registered trademark of The Michigan Nanotechnology Institute for Medicine and Biological Sciences.
MNIMBS logo and graphic designed by Paul D. Trombley, website by Mellon & Associates, LLC
All other company, brand, and product names are or may be trademarks of their respective holders.